scholarly journals Abnormal lipid metabolism in metabolic syndrome: an epigenetic perspective

2016 ◽  
Vol 24 (2) ◽  
pp. 153-160 ◽  
Author(s):  
Ioana Brudașcă ◽  
Mircea Cucuianu
Keyword(s):  
Metabolic Syndrome ◽  
Dna Methylation ◽  
Life Span ◽  
Maternal Obesity ◽  
Maternal Nutrition ◽  
Hdl Cholesterol ◽  
Atherogenic Dyslipidemia ◽  
Epigenetic Changes ◽  
The Metabolic Syndrome ◽  
Increased Risk

Abstract Metabolic syndrome is a complex pathology including central obesity, impaired glucose tolerance/diabetes, an atherogenic dyslipidemia and a prothrombotic state. A new perspective on understanding the mechanisms underlying metabolic syndrome is provided by the epigenetic changes (mainly DNA methylation and histone covalent modifications), which influence gene expression without changing of the DNA sequence. DNA methylation (mainly in carnitine palmitoyltransferase 1A gene) and histone modifications were shown to be associated with VLDL and LDL phenotypes, with hyperglycemia and reduced level of HDL cholesterol, with hypertriglyceridemic waist phenotype and with progression of atherosclerotic occlusion in peripheral arteries. The epigenetic changes can occur in the prenatal period, throughout the life span, and can be transmitted to the offspring. Both poor maternal nutrition and maternal obesity, diabetes and overfeeding can result in epigenetic alterations that amplify the risk of metabolic syndrome for the offspring. Throughout life span, environmental factors, such as nutrition and exercise can induce epigenetic changes influencing the evolution of the metabolic syndrome (through adipocyte metabolism and insulin signaling pathway). The epigenetic modifications are not completely erased during gametogenesis and embryogensis, resulting in a transgenerational transmission of an epigenetic state up to the fifth generation. Epigenetic mechanisms are an interface between environmental stimuli and resulting phenotype by inducing a certain transcriptional state, which may be also transmitted to the next generation(s) and which may predispose to an increased risk for developing metabolic syndrome in the context of a mismatched environment. Elucidating epigenetic modulation might provide additional information about risk evaluation and more targeted therapeutical intervention.

scholarly journals Dietary intake of manganese and the risk of the metabolic syndrome in a Chinese population

2016 ◽  
Vol 116 (5) ◽  
pp. 853-863 ◽  
Author(s):  
Biao Zhou ◽  
Xuefen Su ◽  
Danting Su ◽  
Fangfang Zeng ◽  
Maggie Haitian Wang ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Animal Studies ◽  
Hdl Cholesterol ◽  
Epidemiological Studies ◽  
Inverse Association ◽  
Chinese Adults ◽  
Related Data ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Low Hdl

AbstractAnimal studies have suggested that Mn might be associated with some components of the metabolic syndrome (MetS). A few epidemiological studies have assessed dietary Mn intake and its association with the risk of the MetS and its components among Chinese adults. In this study, we assessed daily dietary Mn intake and its relationship with MetS risk among Chinese adults in Zhejiang Province using data from the 5th Chinese National Nutrition and Health Survey (2010–2012). A total of 2111 adults were included. Dietary Mn intake was assessed using 3-d 24-h dietary recalls; health-related data were obtained by questionnaire surveys, physical examinations and laboratory assessments. The mean intake of Mn was 6·07 (sd 2·94) mg/d for men (n 998) and 5·13 (sd 2·65) mg/d for women (n 1113). Rice (>42 %) was the main food source of Mn. The prevalence of the MetS was 28·0 % (590/2111). Higher Mn intake was associated with a decreased risk of the MetS in men (Q4 v. Q1 OR 0·62; 95 % CI 0·42, 0·92; Ptrend=0·043) but an increased risk in women (Q4 v. Q1 OR 1·56; 95 % CI 1·02, 2·45; Ptrend=0·078). In addition, Mn intake was inversely associated with abdominal obesity (Ptrend=0·016) and hypertriacylglycerolaemia (Ptrend=0·029) in men, but positively associated with low HDL-cholesterol in both men (Ptrend=0·003) and women (Ptrend<0·001). Our results suggest that higher Mn intakes may be protective against the MetS in men. The inverse association between Mn intake and the MetS in women might be due to the increased risk for low HDL-cholesterol.

scholarly journals Living in the Southern Hemisphere: Metabolic Syndrome and Its Components in Amazonian Riverine Populations

2021 ◽  
Vol 10 (16) ◽  
pp. 3630
Author(s):  
Gabriela P. Arrifano ◽  
Jacqueline I. Alvarez-Leite ◽  
Barbarella M. Macchi ◽  
Núbia F. S. S. Campos ◽  
Marcus Augusto-Oliveira ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Southern Hemisphere ◽  
Vulnerable Populations ◽  
Low Income ◽  
Hdl Cholesterol ◽  
Developed Countries ◽  
Atherogenic Dyslipidemia ◽  
Cross Sectional ◽  
The Metabolic Syndrome ◽  
Low Hdl

The metabolic syndrome (MetS) epidemic is a global challenge. Although developing countries (including Brazil, India, and South Africa) present a higher proportion of deaths by cardiovascular diseases than developed countries, most of our knowledge is from these developed countries. Amazonian riverine populations (ARP), as well as other vulnerable populations of the Southern Hemisphere, share low-income and traditional practices, among other features. This large cross-sectional study of ARP (n = 818) shows high prevalence of hypertension (51%) and obesity (23%). MetS was diagnosed in 38% of participants (especially in women and 60–69 years-old individuals) without the influence of ancestry. Only 7–8% of adults had no cardio-metabolic abnormalities related to MetS. Atherogenic dyslipidemia (low HDL-cholesterol) was generally observed, including in individuals without MetS. Still, slight differences were detected between settings with a clear predominance of hypertension in Tucuruí. Hypotheses on possible genetic influence and factors (nutrition transition and environmental pollutants -mercury) are proposed for future studies. Moreover, a roadmap to MetS progression based on the most prevalent components is provided for the development of tailored interventions in the Amazon (initially, individuals would present low HDL-cholesterol levels, later progressing to increased blood pressure characterizing hypertension, and ultimately reaching MetS with obesity). Our alarming results support the need to improve our knowledge on these vulnerable populations.

scholarly journals Metabolic syndrome: what is it and what are the implications?

2005 ◽  
Vol 64 (3) ◽  
pp. 349-357 ◽  
Author(s):  
D. I. Shaw ◽  
W. L. Hall ◽  
C. M. Williams
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Abdominal Obesity ◽  
Vascular Function ◽  
Hdl Cholesterol ◽  
The Metabolic Syndrome ◽  
Obesity And Overweight ◽  
Increased Risk ◽  
Diet And Exercise

Obesity and overweight are linked with a cluster of metabolic and vascular disorders that have been termed the metabolic syndrome. Although there is not yet a universally-accepted set of diagnostic criteria, most expert groups agree that the syndrome is characterised by impaired insulin sensitivity and hyperglycaemia, dyslipidaemia (elevated blood triacyglycerols with depressed HDL-cholesterol), abdominal obesity and hypertension. Based on existing published criteria estimates suggest that the syndrome affects a substantial percentage of the middle-aged and elderly populations of most European countries (10–20%) and confers increased risk of type 2 diabetes (2–8.8-fold) and CVD (1.5–6-fold), as well as having a marked effect on morbidity. Although the pathophysiology is incompletely understood, insulin resistance and abdominal obesity are central to subsequent abnormalities in circulating glucose and lipoproteins, and vascular function that lead to type 2 diabetes, atherosclerosis and CVD. The link between metabolic syndrome, type 2 diabetes and CVD, as well as inability to reverse the present rising rates of obesity, will lead to economically-unsustainable costs of health care in the next 10–20 years. Preventative strategies for metabolic syndrome are required to slow rates of progression and to reduce dependence on costly medical management. A notable development is recent evidence that shows that diet and exercise are more effective than drug treatment in preventing the development of type-2 diabetes in high-risk individuals. The LIPGENE project will investigate dietary fat quality as a strategy for the prevention of metabolic syndrome and identify food chain approaches that can support consumer attempts to alter their dietary patterns.

scholarly journals AB0577 METABOLIC SYNDROME IN PSORIATIC ARTHRITIS SEEMS ASSOCIATED TO INFLAMMATORY STATUS OF THE DISEASE

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1326.1-1326
Author(s):  
C. L. Iñíguez ◽  
J. A. Mosquera Martínez ◽  
L. Fernández-Dominguez ◽  
F. Maceiras-Pan ◽  
C. García-Porrúa ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Disease Activity ◽  
Atherogenic Dyslipidemia ◽  
C Reactive Protein ◽  
Low Disease Activity ◽  
Reactive Protein ◽  
The Metabolic Syndrome ◽  
Inflammatory Status ◽  
Increased Risk ◽  
Patient Reported

Background:Evidence suggests that inflammation plays a causal role in the development of Metabolic Syndrome (MetS) and elevated peripheral levels of proinflammatory mediators, such as C-reactive protein (CRP) confering cardiovascular and metabolic risk.Objectives:The objective of this study was to evaluate Metabolic Syndrome among patients with PsA naïve to biologics and to evaluate its association with inflammatory activity status previous start them.Methods:We performed a retrospective cross-sectional study of a cohort of patients ≥18 years of age, all patients with a diagnosis of PsA (CASPAR criteria), included in the Sueiro Cohort. Patients were managed according to a standard protocol adopted at the Rheumatology outpatient clinic of six hospitals and they were patients on follow-up for at least 6 months. Collected variables included age and gender, blood biochemistry, blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), HLA-B27 and rheumatoid factor, glucocorticoid, NSAID and conventional or biologic DMARD, smoking habit, hyperuricemia, type 2 diabetes mellitus, obesity (BMI kg/m2). MetS was defined by a combination of abdominal obesity, impaired fasting glucose, atherogenic dyslipidemia, and elevated blood pressure. Status of disease activity was supported by tender and swollen joint counts (TJC68 and SJC66) from patients who were going to start treatment with biologics and Patient-reported outcome measure were collected with Patient Global Assessment (0-10 cm) and Patient Pain Assessment (0-10 cm). Remission and low disease activity status was obtained by DAPSA score and its defined cut-off. Tests were two-tailed with a significance level of 5%. Data were analyzed using SPSS V21.0 statistical software (IBM Corp. NY, USA).Results:A total of 416 were included in the study: 222 PsA patients treated with csDMARD kept in remission or low disease activity and 194 patients needed to be treated with bDMARD. The mean age of the patients was 53.0 years (SD: 11.8). Two hundred and twenty-eight were males (56.2%).Fifty-six patients had MetS (13.8%) and it was more frequent in patients who were in clinical activity and they needed biologics (17.9% vs 10.4%, p 0.028) with mean (SD) of DAPSA of 16.7 (11.1). Patients starting treatment with biologics and with MetS had more proportion of patients older than 50 years (24.2 % vs 8.3%, p 0.006) and CRP >5 mgr/L (71.4% vs 52.6%, p 0.042) and DAPSA had higher values than in patients without MetS (18.6 vs 16.2) but there were not significant statistical differences. Binary regression analysis showed increased risk of MetS for age > 50 years old (OR 3.287 [95%CI: 1.258-8.591], p 0.015) and CRP > 5 mgr/L (OR 2.684 [95%CI: 1.141-6.313], p 0.024) but not for gender (OR 2.136 [95%CI: 0.932-4.893], p 0.073) neither for DAPSA>14 (OR 1.539 [95%CI: 0.695-3.409], p 0.288).Conclusion:Patients with PsA active despite csDMARD had more prevalence of MetS and this was associated with those patients over 50 years old and CRP higher than normal values. DAPSA was higher in patients with MetS but without reaching significant statistical difference.References:[1]Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Current Diabetes Reports. 2005;5:70–75Acknowledgements:I have acknowledgements to SOGARE.Disclosure of Interests:None declared.

scholarly journals Relationship between Serum Vitamin D Levels and HDL Cholesterol in Postmenopausal Women from Colombian Caribbean

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Luz Adriana Sarmiento-Rubiano ◽  
José Armando Angarita Ruidiaz ◽  
Héctor Fernando Suarez Dávila ◽  
Alfonso Suarez Rodríguez ◽  
Roberto C. Rebolledo-Cobos ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Postmenopausal Women ◽  
Serum Vitamin ◽  
Hdl Cholesterol ◽  
Serum Vitamin D ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Vitamin D Levels

Background. Previous evidence suggests that metabolic disorders in postmenopausal women could be related with low serum vitamin D levels. For example, vitamin D deficiency has been associated with increased risk factors for cardiovascular disease (CVD), mainly those related with metabolic syndrome.Objective. To assess the relationship between the serum vitamin D (25-OH-D) levels and the metabolic syndrome markers in postmenopausal women.Methods. This descriptive and cross-sectional study was conducted in 183 postmenopausal women of four municipalities from Colombian Caribbean. The serum 25-OH-D levels and the anthropometric and biochemical markers were assessed and correlated with metabolic syndrome.Results. The average value of serum vitamin D (25-OH-D) was 26.34 ± 9.08 ng/mL, and 69.95% of the women had vitamin D levels <30 ng/mL, of which 43.72% were with insufficiency (<30 to >20 ng/mL) and 26.23% with deficiency (<20 ng/mL). Of the evaluated women, the 81.42% seemed to have metabolic syndrome. Through the linear regression, one significant positive association was observed between the HDL cholesterol and the 25-OH-D levels (P=0.014).Conclusion. In the evaluated population in this study, vitamin D deficiency is related with low HDL cholesterol levels.

Schoolchildren born VLBW or VLGA show height-related changes in body composition and muscle function but no evidence of metabolic syndrome risk factors. Results from the NEOLONG study

2016 ◽  
Vol 29 (2) ◽  
Author(s):  
Michael B. Ranke ◽  
Roland Schweizer ◽  
Susanne M. Rodemann ◽  
Andrea Bevot ◽  
David D. Martin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Composition ◽  
Very Low Birth Weight ◽  
Resting Energy Expenditure ◽  
Hdl Cholesterol ◽  
Serum Levels ◽  
Normal Height ◽  
The Metabolic Syndrome ◽  
Short Children ◽  
Increased Risk

AbstractChildren born small for gestational age (SGA) are at risk for the metabolic syndrome (MetS) as adults. We examined whether indicators of MetS could be identified in pre-pubertal children born very preterm.Parameters associated with MetS were studied in 141 pre-pubertal schoolchildren with either very low birth weight (VLBW) or GA <32 weeks (SGA: n=43).At 8.3±0.8 years, 36 children (SGA: n=15) were classified short. There were no differences between the SGA and appropriate for age (AGA) groups; nor were dissimilarities observed between short children and those with normal height for parameters such as body mass index (BMI), serum levels of hormones, HDL cholesterol, triglycerides, glucose, insulin, HOMA-IR, body composition, resting energy expenditure, grip strength and jump force.Neither SGA at birth nor short stature at follow-up (irrespective of size at birth), could be associated with parameters that indicate an increased risk for the MetS during childhood.

Prevalence of metabolic syndrome in never treated mood disordered patientss

2007 ◽  
Vol 30 (4) ◽  
pp. 95
Author(s):  
Valerie Taylor ◽  
Glenda M. MacQueen
Keyword(s):  
Metabolic Syndrome ◽  
Mood Disorders ◽  
Population Attributable Risk ◽  
Disease Process ◽  
Visceral Obesity ◽  
Premature Mortality ◽  
Overweight And Obesity ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Bipolar Patients

Bipolar disorder and major depression are life-shortening illnesses. Unnatural causes such as suicide and accidents account for only a portion of this premature mortality1 Research is beginning to identify that mood disordered patients have a higher incidence of metabolic syndrome, an illness characterized by dyslipidemia, impaired glucose tolerance, hypertension and obesity.2 Metabolic syndrome is associated with an increased risk for a variety of physical illnesses. Hypothesis: Never treated patients with mood disorders have preexisting elevations in the prevalence of the component variables of metabolic syndrome. Central obesity will be especially elevated, predicting increased premature mortality. Methods: We assessed never treated patients with mood disorders for metabolic syndrome and its component variables. Patients were assessed at baseline and followed up at 6-month intervals. All psychiatric pharmacotherapy was documented. Body mass index (BMI) was also obtained and the percentage of deaths attributable to overweight and obesity was calculated using the population attributable risk (PAR). [PAR= ∑[P (RR-1)/RR] Results: Prior to the initiation of treatment, patients did not differ from population norms with respect to metabolic syndrome or BMI. At 2-year follow-up, BMI had increased for unipolar patients 2.02 points and 1.92 points for bipolar patients. (p < .001) This increase in BMI predicted an increase in mortality of 19.4%. Conclusion: An increase in visceral obesity is often the first component of metabolic syndrome to appear and may indicate the initiation of this disease process prematurely in this group. The increase in BMI places patients with mood disorders at risk for premature mortality and indicates a need for early intervention. References 1.Osby U, Brandt L, Correia N, Ekbom A & Sparen P. Excess mortability in bipolar and Unipolar disorder rin Sweden. Archives of General Psychiatry, 2001;58: 844-850 2.Toalson P, Saeeduddin A, Hardy T & Kabinoff G. The metabolic syndrome in patients with severe mental illness. Journal of Clinical Psychiatry, 2004; 6(4): 152-158

Cardiovascular Risk Assessement in Osteoporotic Patients Using Osteoprotegerin as a Reliable Predictive Biochemical Marker

2018 ◽  
pp. 253
Author(s):  
Noora Wael Rasheed ◽  
Ooroba Jameel Taresh
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Cardiovascular Risk ◽  
Serum Level ◽  
Biochemical Markers ◽  
Hdl Cholesterol ◽  
Predictive Marker ◽  
Serum Levels ◽  
Arterial Calcification ◽  
The Metabolic Syndrome

       Some studies indicated a relationship between increased serum levels of osteoprotegerin with arterial calcification and as a result, it leads to the risk of cardiovascular disease. In our study group we selected patients with osteoporosis, with similar age and body mass index for the assessment of the relationship between cardiovascular disease and osteoprotegerin serum level. We took into account the analysis of correlation and association between the presence of distinct patterns of atherosclerosis and associated diseases like high blood pressure,  diabetes mellitus, low HDL cholesterol, increased LDL cholesterol, increased triglycerides and was the case of presence of any type of dyslipidemia, in case of pre-existent treatment. Objective of study was the assessment of osteoprotegerin value as predictive marker for cardiovascular and metabolic risk in osteoporotic patients. Our results showed significant correlations of parathyroid hormone, osteocalcin and biochemical markers of bone with glucose metabolism and lipid were found in our research, maintaining crosstalk between calcium and biochemical markers of bone and cardiovascular risk. The serum level of Osteoprotegerin has been shown to have a large predictive value for the metabolic syndrome as a cardiovascular risk standard in patients with osteoporosis. The osteoprotegerin serum levels were increased in the patients with metabolic syndrome as a protective response facing the atherosclerotic lesions.

Metabolic Syndrome During Menopause

2019 ◽  
Vol 17 (6) ◽  
pp. 595-603 ◽  
Author(s):  
Sezcan Mumusoglu ◽  
Bulent Okan Yildiz
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Central Obesity ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Natural Menopause ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Aging Women

The metabolic syndrome (MetS) comprises individual components including central obesity, insulin resistance, dyslipidaemia and hypertension and it is associated with an increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The menopause per se increases the incidence of MetS in aging women. The effect(s) of menopause on individual components of MetS include: i) increasing central obesity with changes in the fat tissue distribution, ii) potential increase in insulin resistance, iii) changes in serum lipid concentrations, which seem to be associated with increasing weight rather than menopause itself, and, iv) an association between menopause and hypertension, although available data are inconclusive. With regard to the consequences of MetS during menopause, there is no consistent data supporting a causal relationship between menopause and CVD. However, concomitant MetS during menopause appears to increase the risk of CVD. Furthermore, despite the data supporting the association between early menopause and increased risk of T2DM, the association between natural menopause itself and risk of T2DM is not evident. However, the presence and the severity of MetS appears to be associated with an increased risk of T2DM. Although the mechanism is not clear, surgical menopause is strongly linked with a higher incidence of MetS. Interestingly, women with polycystic ovary syndrome (PCOS) have an increased risk of MetS during their reproductive years; however, with menopausal transition, the risk of MetS becomes similar to that of non-PCOS women.

Sign in / Sign up

Export Citation Format

Share Document